Patient Portal

Brian Van Tine, MD, PhD

Assistant Professor, Medicine
Division of Oncology
Section of Medical Oncology

Specialty Areas

Oncology
Sarcoma
Medical Oncology

Board Certifications

Internal Medicine
Medical Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Medical oncology, cancer, sarcoma, soft tissue sarcoma, bone cancer, leiomyosarcoma, liposarcoma

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Center for Advanced Medicine

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171

Education

Education

Medical Degree: University of Alabama at Birmingham 2005
PhD: University of Alabama at Birmingham 2003
Chief Fellow: Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri 2010
BS: University of Arizona, Tucson, Arizona 1995
Residency: Barnes-Jewish Hospital, St. Louis, Missouri 2006
Fellowship: Oncology, Washington University School of Medicine, St. Louis, Missouri 2007

Publication & Research

Publication & Research

The Immune Landscape of Cancer.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research Network., Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I
Immunity. 2019 Aug 20; 51(2)411-412. doi: 10.1016/j.immuni.2019.08.004.

PMID:
    31433971
    [PubMed]
Related citations


Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, Grilley-Olson JE, Maggiore R, Salama NN, Trinkaus K, Van Tine BA, Steuer CE, Saba NF, Oppelt P
Lancet Oncol. 2019 Jul 24; pii: S1470-2045(19)30405-X. doi: 10.1016/S1470-2045(19)30405-X.

PMID:
    31351869
    [PubMed - as supplied by publisher]
Related citations


Incidence and Management of Olaratumab Infusion-Related Reactions.
Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD
J Oncol Pract. 2019 Jul 3; JOP1800761. doi: 10.1200/JOP.18.00761.

PMID:
    31268811
    [PubMed - as supplied by publisher]
Related citations


Management of localized extremity and retroperitoneal soft tissue sarcoma.
Abaricia S, Van Tine BA
Curr Probl Cancer. 2019 Jun 15; pii: S0147-0272(19)30175-8. doi: 10.1016/j.currproblcancer.2019.06.002.

PMID:
    31221500
    [PubMed - as supplied by publisher]
Related citations


Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.
Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM
Cancer Immunol Res. 2019 Aug; 7(8)1237-1243. doi: 10.1158/2326-6066.CIR-18-0940.

PMID:
    31171504
    [PubMed - in process]
Related citations


Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.
Younger E, Ballman K, Lu Y, Pápai Z, Van Tine BA, Attia S, Schöffski P, Reinke D, Tap WD, Jones RL
J Geriatr Oncol. 2019 May 21; pii: S1879-4068(18)30464-8. doi: 10.1016/j.jgo.2019.05.008.

PMID:
    31126845
    [PubMed - as supplied by publisher]
Related citations


Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Prudner BC, Rathore R, Robinson AM, Godec A, Chang SF, Hawkins WG, Hirbe AC, Van Tine BA
Clin Cancer Res. 2019 Aug 15; 25(16)5122-5134. doi: 10.1158/1078-0432.CCR-19-0206.

PMID:
    31113844
    [PubMed - in process]
Related citations


A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG
Cancer. 2019 Jul 15; 125(14)2445-2454. doi: 10.1002/cncr.32084.

PMID:
    31034598
    [PubMed - in process]
Related citations


A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.
Van Tine BA, Agulnik M, Olson RD, Walsh GM, Klausner A, Frank NE, Talley TT, Milhem MM
Cancer Med. 2019 Jun; 8(6)2994-3003. doi: 10.1002/cam4.2136.

PMID:
    31016866
    [PubMed - in process]
Related citations


The Metastatic Spine Disease Multidisciplinary Working Group Algorithms.
Wallace AN, Robinson CG, Meyer J, Tran ND, Gangi A, Callstrom MR, Chao ST, Van Tine BA, Morris JM, Bruel BM, Long J, Timmerman RD, Buchowski JM, Jennings JW
Oncologist. 2019 Mar; 24(3)424. doi: 10.1634/theoncologist.2015-0085err.

PMID:
    30867318
    [PubMed]
Related citations


Clinical Outcomes and Prognostic Features of Angiosarcoma: Significance of Prior Radiation Therapy.
Merfeld E, Gabani P, Spraker MB, Zoberi I, Kim H, Van Tine B, Chrisinger J, Michalski JM
Clin Oncol (R Coll Radiol). 2019 Apr; 31(4)232-241. doi: 10.1016/j.clon.2019.01.006.

PMID:
    30718086
    [PubMed - in process]
Related citations


How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA, Trent JC
Curr Med Res Opin. 2019 Apr; 35(4)623-629. doi: 10.1080/03007995.2019.1570768.

PMID:
    30652922
    [PubMed - in process]
Related citations


Sorafenib for Advanced and Refractory Desmoid Tumors.
Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK
N Engl J Med. 2018 Dec 20; 379(25)2417-2428. doi: 10.1056/NEJMoa1805052.

PMID:
    30575484
    [PubMed - indexed for MEDLINE]
Related citations


Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review.
Riedel RF, Jones RL, Italiano A, Bohac C, Thompson JC, Mueller K, Khan Z, Pollack SM, Van Tine BA
Cancers (Basel). 2018 Nov 1; 10(11)pii: E417. doi: 10.3390/cancers10110417.

PMID:
    30388821
    [PubMed]
Related citations


Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network., Camargo F, Liang H
Cell Rep. 2018 Oct 30; 25(5)1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001.

PMID:
    30380420
    [PubMed - in process]
Related citations


A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.
Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network., Weinstein JN, Mishra L, Akbani R
Cell Syst. 2018 Oct 24; 7(4)422-437.e7. doi: 10.1016/j.cels.2018.08.010.

PMID:
    30268436
    [PubMed - in process]
Related citations


Comprehensive Characterization of Cancer Driver Genes and Mutations.
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, MC3 Working Group., Cancer Genome Atlas Research Network., Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L
Cell. 2018 Aug 9; 174(4)1034-1035. doi: 10.1016/j.cell.2018.07.034.

PMID:
    30096302
    [PubMed]
Related citations


Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M
Ann Oncol. 2018 Sep 1; 29(9)1995-2002. doi: 10.1093/annonc/mdy253.

PMID:
    30084934
    [PubMed - in process]
Related citations


Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Cancer Genome Atlas Research Network., Rätsch G
Cancer Cell. 2018 Aug 13; 34(2)211-224.e6. doi: 10.1016/j.ccell.2018.07.001.

PMID:
    30078747
    [PubMed - indexed for MEDLINE]
Related citations


The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Cancer Genome Atlas Research Network., Spellman PT, Rathmell WK, Linehan WM
Cell Rep. 2018 Jun 19; 23(12)3698. doi: 10.1016/j.celrep.2018.06.032.

PMID:
    29925010
    [PubMed]
Related citations

Areas of Research Interest

Our focus is on understanding the genomics of osteosarcoma, leiomyosarcoma and rarer forms of sarcoma. Using mouse genetics, human tumor xenografting and cancer biology we strive to identify druggable targets that can be used in the clinic.